Advanced in Chromosome 13q Deletion

Victoria Castel

Valencia, VC, ES 
Advanced in Chromosome 13q Deletion
Valencia, VC, ES 
OverviewLocationsClinical Research

Overview

Victoria Castel practices in Valencia, Spain. Ms. Castel is rated as an Advanced expert by MediFind in the treatment of Chromosome 13q Deletion. Her top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, and Chromosome 13q Deletion.

Her clinical research consists of co-authoring 73 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Chromosome 13q Deletion.

Gender
Female

Locations

Valencia, VC, Spain
Other Locations
Barcelona, CT 08002, Spain
Spain
Campanar, VC 48009, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomised Phase IIb Trial of Bevacizumab Added to Temozolomide ± Irinotecan for Children With Refractory/Relapsed Neuroblastoma - BEACON-Neuroblastoma Trial
A Randomised Phase IIb Trial of Bevacizumab Added to Temozolomide ± Irinotecan for Children With Refractory/Relapsed Neuroblastoma - BEACON-Neuroblastoma Trial
Enrollment Status: Active_not_recruiting
Publish Date: May 14, 2024
Intervention Type: Drug
Study Drugs: Bevacizumab, Temozolomide, Irinotecan, Topotecan, Dinutuximab Beta, Cyclophosphamide
Study Phase: Phase 2
A Phase I/II Dose Schedule Finding Study of ch14.18/CHO Continuous Infusion Combined With Subcutaneous Aldesleukin (IL-2) in Patients With Primary Refractory or Relapsed Neuroblastoma
A Phase I/II Dose Schedule Finding Study of ch14.18/CHO Continuous Infusion Combined With Subcutaneous Aldesleukin (IL-2) in Patients With Primary Refractory or Relapsed Neuroblastoma
Enrollment Status: Unknown
Publish Date: July 14, 2020
Intervention Type: Drug
Study Drugs: ch14.18/CHO, Aldesleukin, Isotretinoin
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

73 Total Publications

Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 08, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Castel's expertise for a condition
ConditionClose
View All 10 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile